Chinook Therapeutics, Inc.
Chinook Therapeutics, Inc., a clinical-stage biotechnology company, focuses on the discovery, development, and commercialization of precision medicines for kidney diseases. The company's lead clinical program is atrasentan, a Phase III endothelin recepto…
Biotechnology
US, Seattle [HQ]
KDNY/Financial Reporting
Income Statements
Profit & Loss · 8 Statements · From 2022 to 2015Configuration
In Million USD. Margins, Growth Rates In %
| Metric | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | |
|---|---|---|---|---|---|---|---|---|---|
| Revenue | 72.00 | 50.00 | 17.00 | 15.00 | 17.00 | - - | 51.00 | 6.00 | |
|
EPS
|
- - | - - | - - | - - | -1.11 | -6.20 | -2.22 | -2.87 | |
| Diluted in mil. | - - | - - | - - | - - | -1.11 | -6.20 | -2.22 | -2.87 | |
|
Profit
|
72.00 | 50.00 | 16.00 | 14.00 | 16.00 | - - | 49.00 | 4.00 | |
| Gross Margin | 99.88 | 98.92 | 96.76 | 96.13 | 96.79 | 48.97 | 96.73 | 71.90 | |
| Pre Tax | -39.00 | -69.00 | -103.00 | -96.00 | -46.00 | -83.00 | -99.00 | -180.00 | |
| Profit Margin | -53.86 | -137.50 | -598.80 | -637.24 | -269.55 | -10,111.85 | -192.17 | -2,941.81 | |
| ETR | 0.25 | 30.80 | -11.01 | -0.81 | -0.71 | 2.40 | -2.11 | -2.41 | |
| Net | -39.00 | -91.00 | -91.00 | -95.00 | -46.00 | -81.00 | -101.00 | -184.00 | |
| Profit Margin | -53.73 | -179.85 | -532.88 | -632.05 | -271.47 | -9,869.65 | -196.22 | -3,012.65 | |
| EBITDA | -13.00 | -71.00 | -106.00 | -101.00 | -19.00 | -53.00 | -57.00 | -164.00 | |
| EBITDA Margin | -18.59 | -141.79 | -617.51 | -671.84 | -112.68 | -6,527.45 | -110.74 | -2,679.44 | |
| Operating Income | -13.00 | -71.00 | -106.00 | -101.00 | -19.00 | -56.00 | -99.00 | -185.00 | |
| Operating Margin | -18.59 | -141.79 | -617.51 | -671.84 | -115.69 | -6,798.91 | -191.84 | -3,020.28 | |
| Interest Income | - - | - - | - - | - - | - - | - - | - - | - - | |
| Loss | -86.00 | -122.00 | -123.00 | -116.00 | -19.00 | -55.00 | -130.00 | -179.00 | |
| Cost of Revenue | - - | - - | - - | - - | - - | - - | -1.00 | -1.00 | |
|
Operating Expenses
|
-86.00 | -121.00 | -123.00 | -115.00 | -19.00 | -55.00 | -130.00 | -179.00 | |
| R&D | -58.00 | -87.00 | -89.00 | -75.00 | -17.00 | -36.00 | -96.00 | -141.00 | |
| G&A | -27.00 | -34.00 | -33.00 | -36.00 | -2.00 | -19.00 | -31.00 | -36.00 | |
| SG&A | -27.00 | -34.00 | -33.00 | -36.00 | -2.00 | -19.00 | -31.00 | -36.00 | |
| S&M | - - | - - | - - | - - | - - | - - | - - | - - | |
| Depreciation and Amortization | - - | -2.00 | -3.00 | -4.00 | - - | -1.00 | -4.00 | -5.00 | |
| Interest Expenses | - - | -2.00 | - - | - - | - - | - - | - - | -7.00 | |
| Other Expenses | -25.00 | -2.00 | -3.00 | -5.00 | -26.00 | -27.00 | - - | -4.00 | |
|
WA Shares Outstanding
|
44,706.00 | 65,200.00 | 72,901.00 | 78,812.00 | 42.00 | 13.00 | 45.00 | 64.00 | |
| Diluted | 44,706.00 | 65,200.00 | 72,901.00 | 78,812.00 | 42.00 | 13.00 | 45.00 | 64.00 |